News & Updates

Topical corticosteroid (TCS) phobia (TOPICOP) commonly exists among patients with chronic hand eczema (CHE) and often leads to poor treatment adherence, suggests a recent study.

First-line endocrine therapy (ET) plus palbociclib (palb/ET) performs better than mono-chemotherapy in improving time to treatment failure (TTF) and progression-free survival (PFS) in women with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (mBC), as shown by the results of the phase III PADMA trial.

Treatment with trastuzumab deruxtecan (T-DXd) results in longer progression-free survival (PFS) in patients with hormone receptor–positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC) compared with physician’s choice of chemotherapy, according to the results of the phase III DESTINY-Breast06 study presented at SABCS 2024. In addition, no new safety signals have been identified.

The two-bag method is both safe and effective for the management of diabetic ketoacidosis (DKA) relative to the one-bag method, a study has shown.

Initiation of sacubitril-valsartan with spironolactone during hospitalization for acute decompensated heart failure (ADHF) does not result in more adverse drug reactions (ADRs), reports a study. However, patients on this regimen tend to develop hyperkalemia.

In critically ill patients with community-acquired pneumonia (CAP), treatment with corticosteroids has significantly reduced the need for mechanical ventilation, while use of hydrocortisone has prevented many hospital deaths.